"Inovio could certainly go much higher with several vaccines in development. If the company's CEO announces any positive news next week, the stock will probably continue its upward trajectory", Keith Speights, September 7, 2013, The Motley Fool
The list of institutional investors with positions in Inovio looks like a who's-who of major firms, with Vanguard standing atop the group with nearly 3.5 million shares as of June 30. It seems quite possible that a few of these big investors could have been scooping up more shares over the last week. The volume of shares traded was exceptionally high, with more than 16 million shares bought and sold on Friday. For comparison, Inovio's average daily volume over the past three months was just over 8 million shares.
The most likely catalyst for all this action appears to be that Inovio is presenting at two upcoming investor conferences. Dr. J. Joseph Kim, Inovio's CEO, will speak at the Rodman & Renshaw Global Investment Conference on Sept. 10 and at the Stifel Nicolaus Weisel Healthcare Conference on Sept. 12. Perhaps next week will better explain the reason behind the heavy buying activity over the past few days
News 
Market Data 
Discover 
AI
